Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2023-03-08
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well testosterone (enanthate or cypionate) and olaparib work
in treating patients with prostate cancer that has progressed despite hormonal therapy.
Hormonal therapy, such as leuprolide, may lessen the amount of male sex hormones made by the
body. In patients that have developed progressive cancer in spite of standard hormonal
treatment (i.e. castration-resistant prostate cancer), administering testosterone may result
in regression of tumors by causing DNA damage in cancer cells that have adapted to low
testosterone conditions. Olaparib may stop the growth of tumor cells by blocking some of the
enzymes involved in repairing DNA damage. Therefore, giving testosterone and olaparib
together may work better in treating castration-resistant prostate cancer by generating DNA
damage that the cancer cell is unable to repair.